DRUG DOSE OMISSION Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.

The primary efficacy variable for this study is the YMRS total score change from baseline to Day 28 (LOCF).; To evaluate the effectiveness of quetiapine fumarate; To evaluate the relationship between the serum brain-derived neurotrophic factor and quetiapine fumarate; To evaluate the safety and tolerability of quetiapine fumarate

The primary objective of this study is to evaluate the efficacy of quetiapine fumarate in improving agitation and aggression symptoms for the schizophrenic patients; The response rate of quetiapine in improving agitation and aggression symptoms - the efficacy of quetiapine - the safety and tolerability of quetiapine - differences between quetiapine and haloperidol

The primary efficacy variable is the change in aggression between admission and day 8 of treatment with Quetiapine XR as measured by the OAS.; Measuring psychotic symptomatology change from baseline in BPRS-Total Score in aggressive, psychotic patients managed with Quetiapine XR; Measuring the incidence of adverse events (including Extrapyramidal symptoms) by the change from baseline in SAS and BAS and subjective reports; Measuring the incidence of concomitant benzodiazepine and other permitted medication use

Primarily we will seek to show that Quetiapine is superior to placebo in terms of reducing core eating disorder symptoms on the Yale-Brown-Cornell Eating Disorder Scale (YBC-EDS) and the Eating Disorders Inventory-2.; We seek to show that Quetiapine is superior to placebo in reducing anxiety, depression, obsessionality, or weight gain in patients with AN. We also will seek to show that Quetiapine is superior to placebo at reducing positive and negative symptoms.

The primary outcome will be the change from baseline in PTSD symptomatology at the week 8 timepoint.; The secondary outcome will be the change from baseline in PTSD symptomatology at the Week 8 timepoint.

Time to first resolution of delirium; Days in delirium during the study; Duration of delirium; Severity of delirium (highest Nu-DESC score, mean episode Nu-DESC score); ICU and hospital mortality; ICU and hospital length of stay; Length of mechanical ventilation; Time spent deeply sedated (RASS <3); Episodes of subject-initiated device removal; Use of haloperidol therapy (including total dose in haloperidol equivalents during the study, number of doses, number of days of therapy, use of rescue IV haloperidol); Average daily and maximum total antipsychotic drug dose in haloperidol equivalents; Duration of study drug administration; Use of benzodiazepines; Use of opioids; QTc prolongation; Extrapyramidal symptoms; Neuroleptic malignant syndrome

The primary objective is to determine whether quetiapine can increase total sleep time and reduce time awake in patients with AD and sleep disturbance.; Dose-response relationship of quetiapine and sleep in AD patients?; Are there sleep architecture changes from quetiapine?; Do the primary sleep variables change relative to placebo at any weekly time or dose point?; Are caregivers, blind to treatment status, able to detect changes in sleep quality in the patients for quetiapine relative to placebo?; Does quetiapine used at single bedtime dosing for potential nighttime soporific effect have a measurable impact on neuropsychiatric symptoms other than insomnia?

If you think you may have a medical emergency, call your doctor or 911 immediately.

By accessing this website, you are indicating your acknowledgement and acceptance of these Terms of Use. These Terms of Use are subject to change by WinFirst LLC at any time in its discretion. Your use of WinFirst LLC Site after such changes are implemented constitutes your acknowledgement and acceptance of the changes. Please consult these Terms of Use regularly.
PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.